Inicio › Linfoma de Burkitt › California

Ensayos clínicos de Linfoma de Burkitt en California

21 estudios sobre Linfoma de Burkitt buscan participantes en California.

Ciudades en California

Texto oficial del estudio (inglés)

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

Research Site, Duarte

ReclutandoFase 1/2

Edades de 12 en adelante · Todos los sexos · Actualizado el 13 nov 2026 · NCT07109219

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

Children's Hospital Los Angeles, Los Angeles
Lucile Packard Children's Hospital, Stanford University, Palo Alto

ReclutandoFase 1

Edades de 0 a 18 · Todos los sexos · Actualizado el 13 nov 2026 · NCT06173518

Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma

City of Hope Medical Center, Duarte
City of Hope at Irvine Lennar, Irvine

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 13 nov 2026 · NCT07758673

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

City of Hope Comprehensive Cancer Center, Duarte
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
UC San Diego Moores Cancer Center, La Jolla
y 1 más

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT03739814

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Kaiser Permanente Downey Medical Center, Downey
Kaiser Permanente-Fontana, Fontana
Loma Linda University Medical Center, Loma Linda
y 13 más

ReclutandoFase 2

Edades de 1 a 30 · Todos los sexos · Actualizado el 12 nov 2026 · NCT04546399

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Kaiser Permanente-Deer Valley Medical Center, Antioch
Community Cancer Institute, Clovis
UC Irvine Health Cancer Center-Newport, Costa Mesa
y 26 más

ReclutandoFase 3

Edades de 18 a 39 · Todos los sexos · Actualizado el 3 nov 2026 · NCT03150693

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Children's Hospital Los Angeles ( Site 1006), Los Angeles

ReclutandoFase 1/2

6 Months – 25 Years · Todos los sexos · Actualizado el 30 oct 2026 · NCT06395103

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Loma Linda University Medical Center, Loma Linda
Miller Children's and Women's Hospital Long Beach, Long Beach
UCSF Benioff Children's Hospital Oakland, Oakland
y 4 más

ReclutandoFase 2

365 Days · Todos los sexos · Actualizado el 27 oct 2026 · NCT06317662

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Kaiser Permanente Downey Medical Center, Downey
Loma Linda University Medical Center, Loma Linda
Miller Children's and Women's Hospital Long Beach, Long Beach
y 9 más

ReclutandoFase 2

366 Days – 46 Years · Todos los sexos · Actualizado el 27 oct 2026 · NCT06124157

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

City of Hope, Duarte
Valkyrie Clinical Trials, Los Angeles

ReclutandoFase 1/2

Edades de 13 a 90 · Todos los sexos · Actualizado el 26 oct 2026 · NCT06533579

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

University of California, San Francisco, San Francisco

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 26 oct 2026 · NCT04545762

Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia

City of Hope Medical Center, Duarte

ReclutandoFase 1

Edades de 12 a 55 · Todos los sexos · Actualizado el 16 oct 2026 · NCT07133997

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

UC Irvine, Orange

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 14 oct 2026 · NCT07648264

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 14 oct 2026 · NCT07069699

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

Research Site, Duarte
Research Site, Los Angeles
Research Site, Palo Alto

ReclutandoFase 1/2

Edades de 12 en adelante · Todos los sexos · Actualizado el 13 oct 2026 · NCT06137118

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

City of Hope Medical Center, Duarte
City of Hope at Irvine Lennar, Irvine
UC San Diego Moores Cancer Center, La Jolla
y 1 más

ReclutandoFase 2

Edades de 18 a 54 · Todos los sexos · Actualizado el 13 oct 2026 · NCT06918431

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Kaiser Permanente Downey Medical Center, Downey
City of Hope Comprehensive Cancer Center, Duarte
Loma Linda University Medical Center, Loma Linda
y 14 más

ReclutandoFase 3

365 Days – 25 Years · Todos los sexos · Actualizado el 25 ago 2026 · NCT03959085

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

Children's Hospital Los Angeles, Los Angeles
Children's Hospital Orange County, Orange
UCSF School of Medicine, San Francisco

ReclutandoFase 2

Edades de 7 a 25 · Todos los sexos · Actualizado el 19 ago 2026 · NCT05082519

AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas

Stanford University, Palo Alto

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 12 ago 2026 · NCT06340737

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

City of Hope, Duarte

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 5 nov 2025 · NCT04260022

The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL

City of Hope, Duarte
Children's Hospital Los Angeles, Los Angeles
UCLA Mattel Children's Hospital, Los Angeles
y 2 más

ReclutandoFase 2

Edades de 1 a 25 · Todos los sexos · Actualizado el 4 may 2025 · NCT03509961

De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.